Abbott to pay up to $575 million for Neurocrine's endometriosis drug
This article was originally published in Scrip
Executive Summary
Abbott is to pay the US biopharmaceutical company Neurocrine Biosciences $75 million up front for global rights to its next-generation gonadotropin-releasing hormone (GnRH) antagonist portfolio, which includes its lead product elagolix.